Theravance Biopharma (NASDAQ: TBPH) is a biopharmaceutical company that develops and commercializes medicines, with its primary commercial asset being a royalty interest in GSK's Trelegy Ellipta respiratory franchise. The company generates revenue through royalty payments tied to net sales of Trelegy (fluticasone furoate/umeclidinium bromide/vilanterol), a once-daily triple-combination therapy approved for COPD and asthma. Theravance Biopharma also holds a pipeline asset in ampreloxetine, for which it received funding from Royalty Pharma (RPI) structured as a contingent liability accreting based on estimated future royalty payments, subject to FDA approval probability. As of December 31, 2025, the company employed 90 people, with its US operations based in northern California. The company announced an organizational restructuring in March 2026. CEO Rick E. Winningham leads the company.

Revenue model

Royalty-based revenue model. Primary income is royalties from GSK's sales of Trelegy Ellipta, received through a royalty interest arrangement. Milestone payments from development or commercialization partners represent an additional potential revenue stream. The ampreloxetine program is financed via a funding arrangement with Royalty Pharma, structured as a contingent liability against future royalties.

Products and services

Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol): once-daily triple-combination inhaled therapy approved for COPD and asthma; Theravance Biopharma holds a royalty interest in this product commercialized by GSK. Ampreloxetine: pipeline asset in development, with FDA approval probability a key variable as of the FY2025 10-K filing.

Customers and end markets

End markets are COPD and asthma patients. Commercial revenues depend on GSK's sales performance of Trelegy across major markets. Royalty Pharma (RPI) is a key financial partner funding the ampreloxetine program.

Value-chain role

Royalty holder and drug developer. Theravance Biopharma does not directly commercialize Trelegy; GSK handles manufacturing and sales. Theravance receives royalties on those sales. For pipeline assets, the company conducts clinical development while relying on partners for commercialization.

Geographic exposure

Trelegy competes in US, European, and Japanese markets per FY2025 10-K disclosure. US operations are headquartered in northern California.

Competitors

AstraZeneca (Breztri Aerosphere), Chiesi Farmaceutici (Trimbow), Novartis (Enerzair Breezhaler), GlaxoSmithKline (Nucala), Boehringer Ingelheim (Spiriva), AstraZeneca (Symbicort)

Source: SEC 10-K, filed 2026-03-23

Industry: Pharmaceutical Preparations